🔎 Trials Near Me

Home › Bronchiolitis Obliterans Syndrome › Ohio

Bronchiolitis Obliterans Syndrome clinical trials in Ohio

8 studies for Bronchiolitis Obliterans Syndrome are looking for participants at sites in Ohio.

Cities in Ohio

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

  • Cinn Children Hosp Medical Center, Cincinnati
RecruitingPhase 2
Ages 1 to 18 · All sexes · Updated Sep 2, 2026 · NCT07354074

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

  • The Ohio State University, Columbus
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05919511

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

  • The Ohio State University Wexner Medical Center, Columbus
RecruitingObservational study
Ages 7 and older · All sexes · Updated Jul 14, 2026 · NCT07434869

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

  • The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Jun 16, 2026 · NCT04710576

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

  • Cleveland Clinic Foundation, Cleveland
Recruiting
Ages 18 and older · All sexes · Updated May 14, 2026 · NCT06464926

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

  • Oncology Hematology Care Clinical Trials, LLC, Cincinnati
  • Cleveland Clinic, Cleveland
  • The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561

Freedom-1 Study for Chronic Knee Pain

  • Orthopedic Associates of Southwest Ohio, Dayton
  • Premier Pain Treatment, Loveland
  • Kettering Health, Miamisburg
Recruiting
Ages 18 and older · All sexes · Updated Feb 13, 2025 · NCT03877653

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.